Anthrax Treatment Market Size & Share, by Anthrax Type (Cutaneous, Inhalation, Gastrointestinal, Injection); Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, E-commerce, Drug Stores); Drug Class (Fluoroquinolone, Tetracycline) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5771
  • Published Date: Mar 01, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Anthrax Treatment Market size is poised to reach USD 2 Billion by the end of 2036, growing at a CAGR of 8% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of anthrax treatment was USD 720 Million. The reason behind the growth is impelled by the growing population of animals across the globe owing to immigration and births, seasonal or other environmental changes, or it can be fueled by mechanisms that depend on density. For instance, the number of cattle worldwide increased from roughly 937 million in 2021 to over 920 million in 2022.

The growing awareness is believed to fuel the anthrax treatment market growth. Raising public awareness among households in remote areas has led to an increase in the ability of the workers to receive emergency medical care and recognizing the need for quick medical attention in the event of symptoms critical to the success of the anthrax treatment process.


Anthrax Treatment Market
Get more information on this report: Request Free Sample PDF

Anthrax Treatment Market: Growth Drivers and Challenges

Growth Drivers

  • Rising Burden of Zoonotic Disorders – Bacillus anthracis, a gram-positive rod, is the source of the zoonotic infection anthrax, which are facultative anaerobic microbes that produce toxins and are encapsulated. According to the World Health Organization (WHO), zoonoses account for around 60% of newly discovered infectious illnesses that are documented worldwide.
  • Growing Rate of Biological Attacks- One of the most likely agents to be employed in a biological strike is the bacteria that produces anthrax, Bacillus anthracis which has been employed in biowarfare and bioterrorism since 1914, and a tiny quantity is all that is needed to infect a big number of individuals.
  • Increasing Agriculture Industry- Nearly every continent has seen reports of anthrax, and agricultural areas with neutral or alkaline, calcareous soils are the most typical locations for the disease which is acknowledged on a global scale as a significant public health and economic issue. For instance, globally, the agriculture industry is expected to expand by over 5% between 2024 and 2028, reaching a market size of around USD 4 trillion by that year.
  • Surging Prevalence of Rare Diseases- In the industrialized world, anthrax is quite uncommon; it is more prevalent in Africa and central and southern Asia resulting from breathing in bacillus anthracis spores.

Challenges

  • Lack of Awareness - One of the key elements contributing to the illness outbreaks is cattle owners' ignorance of anthrax which has resulted from inadequate surveillance, monitoring, and disease reporting; lack of public knowledge; unfettered mobility; inefficient management; and vaccine regimens. An inadequate understanding of anthrax and how it spreads is a major contributing factor in human cases which might result from contact with contaminated raw meat or blood and the slaughter of sick animals.
  • Moreover, the recurrence of anthrax outbreaks in various parts of the world calls for increased awareness since it is imperative to remain vigilant to avoid, identify, and contain outbreaks.
  • Complexity of diagnosis may increase the need for specialized laboratory tests causing delays in the treatment
  • Exorbitant cost of treatment is expected to limit its accessibility in lower-economic regions.

Anthrax Treatment Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~8%

Base Year Market Size (2023)

~ USD 720 Million

Forecast Year Market Size (2036)

~ USD 2 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Anthrax Treatment Segmentation

Anthrax Type (Cutaneous, Inhalation, Gastrointestinal, Injection)

The Inhalation segment in the anthrax treatment market is estimated to gain a robust revenue share of 44% in the coming years owing to the growing bioterrorism. The infectious condition known as inhalation or respiratory anthrax is brought on by breathing in the bacterium's spores which is the most lethal type of the illness and frequently results in death even with therapy.  Early warning signs and symptoms include Flu-like symptoms, such as sore throat, low temperature, exhaustion, and muscular pains, that last for a few hours or days, and within two to five days, a high fever, a fast heartbeat, and severe dyspnea will manifest. These symptoms could last for two or three days before seemingly disappearing for one or two days, and may then recur, causing severe dyspnea, dyspnea breathing, and shock.

The accumulation of B. anthracis spores in the lung alveoli is caused by inhaling anthrax which is more lethal and challenging to cure owing to these factors, anthrax inhalation is seen as a possible bioterrorism risk since it is the most dangerous kind, and if treatment is delayed, it can be fatal. For instance, the leading cause of death for a population that is exposed and unprotected to anthrax is inhalation, with an untreated mortality rate of more than 95%. Particularly, Inhaling anthrax nearly usually results in death without medical attention, and the mortality rate with current therapy is over 40%.

Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, E-commerce, Drug Stores)

The hospitals pharmacies segment in the anthrax treatment market is set to garner a notable revenue share shortly. The important infrastructure for preventing an anthrax attack includes hospitals and acute care medical institutions since physicians can treat anthrax patients with a variety of treatments, such as antitoxin and antibiotics which is considered important because if one healthcare worker becomes incapacitated, it might have a detrimental effect on the care of dozens or more patients.

Our in-depth analysis of the global anthrax treatment market includes the following segments:

          Anthrax Type

  • Cutaneous
  •  Inhalation
  • Gastrointestinal
  •  Injection

          Distribution Channel

  • Hospitals Pharmacies
  •  Retail Pharmacies
  •  E-commerce
  •  Drug Stores

          Drug Class

  • Fluoroquinolone
  •  Tetracycline

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Anthrax Treatment Industry - Regional Synopsis

North American Market Forecast

Anthrax Treatment market in North America is predicted to account for the largest share of 35% by 2036 impelled by the rising spending in healthcare. This has led to an increased awareness of potential health threats from several rare disorders and has also encouraged more research and development in infectious disease treatment in the region. According to estimates, in 2021, U.S. health spending climbed by more than 2% to reach around USD 4 trillion. In addition, terrorists can strike the United States by using chemical, biological, radiological, or nuclear (CBRN) weapons, therefore along with other federal agencies, the FDA is striving to ensure that the American public has access to sufficient quantities of medications and vaccines.

APAC Market Statistics

The Asia Pacific anthrax treatment market is estimated to be the second largest, during the forecast timeframe led by the growing livestock farming. The welfare of the rural populace in India is greatly influenced by the livestock sector which is a crucial and interacting component in India's mixed farming system.

Research Nester
Anthrax Treatment Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Anthrax Treatment Market

top-features-companies
    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Integrated Bio Therapeutics Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Bayer AG
    • Zydus Group
    • GC Biopharma, corp.
    • BlueWillow Biologics.
    • Emergent BioSolutions
    • ARISTO Pharmaceuticals Private Limited

In-the-news

In The News

  • Emergent BioSolutions received approval from the US Food and Drug Administration (FDA) for, Cyfendus an adjuvant-packed adsorbed version of the anthrax vaccination approved for usage in post-exposure prophylaxis in adults between the ages of 18 and 65.
  • GC Biopharma, corp. applied to obtain approval from the Korean Ministry of Food and Drug Safety (MFDS) for, "GC1109", an anthrax vaccine developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA), that contains protective antigen (PA), and will be the first recombinant anthrax vaccine in history if it is authorized to aid in the preparation for a possible bioterrorism attack and the ensuing national emergency.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5771
  • Published Date: Mar 01, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing population of animals across the globe and the growing awareness are the major factors driving the growth of the market.

The market size of anthrax treatment is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.

The major players in the market are Integrated Bio Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Bayer AG, Zydus Group, GC Biopharma, corp., BlueWillow Biologics., ARISTO Pharmaceuticals Private Limited, Takeda Pharmaceutical Company Limited, and others.

The Inhalation segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Anthrax Treatment Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying